Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.000.81%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -81.97% | -44.14% | -20.67% | -12.20% | -42.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.97% | -44.14% | -20.67% | -12.20% | -42.41% |
| Cost of Revenue | 67.49% | -53.27% | -75.49% | -83.77% | -93.28% |
| Gross Profit | 188.17% | -38.07% | -79.29% | -89.01% | -111.28% |
| SG&A Expenses | -17.74% | -23.63% | -36.82% | -40.62% | -25.55% |
| Depreciation & Amortization | -18.25% | -59.73% | -73.29% | -80.02% | -76.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.94% | -37.87% | -54.58% | -60.68% | -48.10% |
| Operating Income | 34.01% | 36.97% | 47.50% | 46.14% | 7.50% |
| Income Before Tax | -8,199.40% | -287.80% | -72.13% | -15.47% | 101.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8,199.40% | -287.80% | -72.13% | -15.47% | 101.31% |
| Earnings from Discontinued Operations | 231.08% | 242.33% | -33.87% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.57% | -17.93% | -61.24% | -75.41% | 62.79% |
| EBIT | 34.01% | 36.97% | 47.50% | 46.14% | 7.50% |
| EBITDA | 47.34% | 49.94% | 62.34% | 60.35% | 4.94% |
| EPS Basic | 64.46% | 68.92% | 68.10% | 42.21% | 37.69% |
| Normalized Basic EPS | -487.39% | 59.47% | 77.45% | 84.92% | 102.85% |
| EPS Diluted | 64.46% | 68.92% | 68.10% | 42.21% | 37.69% |
| Normalized Diluted EPS | -487.39% | 59.47% | 77.45% | 84.92% | 102.85% |
| Average Basic Shares Outstanding | 7,062.83% | 4,088.34% | 395.67% | 268.66% | 189.91% |
| Average Diluted Shares Outstanding | 7,062.83% | 4,088.34% | 395.67% | 268.66% | 189.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |